
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.
Europe's largest annual dermatology meeting, the






